-
Risk of Abdominal Hernia Repair in Patients With Intestinal Stoma in Italy: A Real-World Analysis
Sep 9, 2025, 16:22 PM -
How Societal Is Sweden? A Study of Inclusion of Societal Costs in Swedish Reimbursement Decisions
Sep 9, 2025, 16:22 PM -
A Nonactive Implant for the Treatment of Chronic Gastro-esophageal Reflux Disease: A Cost-Effectiveness Evaluation From the Perspective of German Healthcare
Sep 9, 2025, 16:22 PM -
The Phantom Menace: How Consultations and Appeals During NICE HST Appraisals Contribute to Delays in Patient Access
Sep 9, 2025, 16:22 PM -
Preliminary Real-World Results of a Community Pharmacy-Based Intervention in COPD: Evidence From the Chronic Diseases From A to Z Program
Sep 9, 2025, 16:22 PM -
Reconsidering Generic Utilities: Implications for Equitable Health Technology Appraisal
Sep 9, 2025, 16:22 PM -
Validation of a Natural Language Processing Solution (REALLI) Compared to Manual Review by Physicians of Electronic Health Records (EHR) From Patients With HER2+ Metastatic Breast Cancer
Sep 9, 2025, 16:22 PM -
Timing Matters: Missed Opportunity to Prevent RSV Cases in Older Adults in Germany: A Markov Model Analysis
Sep 9, 2025, 16:22 PM -
Do We Need to Measure Social Impact of Innovative Drugs?
Sep 9, 2025, 16:22 PM -
Artificial Intelligence in Pharmaceutical Payer Decision Making—Assessing Current Use, Strategic Intent, and Infrastructure Readiness
Sep 9, 2025, 16:22 PM -
Structured Expert Elicitation for Survival Outcomes: Insights From NICE Technical Support Document 26
Sep 9, 2025, 16:22 PM -
What Tips the Scale Toward Reimbursement? A Dutch-led Comparison of Pharmacoeconomic Evaluations Across the Netherlands, Sweden, and the United Kingdom
Sep 9, 2025, 16:22 PM -
Evaluating Treatment Benefit and Tolerability Based on Responder and Time-to-Event Analysis of Patient-Reported Outcomes in Cancer Clinical Trials: A Scoping Review
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Iptacopan vs. C5 Inhibitors in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Naïve to Complement Inhibitors in the Brazilian Private Healthcare System
Sep 9, 2025, 16:22 PM -
Missing Health State Utility Values (HSUV) in NICE Oncology Appraisals: A Systematic Review of Utility Data Reporting and Handling Practices
Sep 9, 2025, 16:22 PM -
Predicting Self-Efficacy in Managing Type 2 Diabetes: Results From a Low-Income, Less Educated Community of Quetta City, Pakistan
Sep 9, 2025, 16:22 PM -
The DM77 and Rare Diseases: Analysis of Regional Legislation in Italy
Sep 9, 2025, 16:22 PM -
Modeling Physician Prescribing Decisions Based on Patient Characteristics for Positioning of a Novel Treatment Entering a Well-Established Category
Sep 9, 2025, 16:22 PM -
Trends and Disparities in Prostate Cancer Incidence Prevalence and Survival: A SEER Analysis 2000-2022
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of Add-On Vericiguat to Standard Treatment in Thai Patients With Heart Failure and Reduced Ejection Fraction
Sep 9, 2025, 16:22 PM
